Abacus Life partners with Lorisco Life

Alternative asset manager and a direct buyer of life insurance Abacus Life , and Lorisco Life , a health prediction company using modern proteomics and machine learning to accurately forecast health events, announced a new partnership and product launch to improve longevity-based health prediction and actuarial technology.

The Lorisco PREADISAN risk score is a novel assessment and planning tool that generates individualized insights beyond traditional statistics-based life expectancy opinions. The PREADISAN risk score introduces blood-based proteomic biomarker analysis coupled with clinically driven artificial intelligence models that assess mortality risks. The PREADISAN risk score is a first of its kind tool that integrates biological insights with the assessment of mortality risk over time.

“We are proud to be partnering with Abacus Life to enable how health predictions are customized for end users through proteomics and machine learning. The PREADISAN risk score enables the Abacus team to offer an unprecedented level of tailored solutions for their clients.” – Howard Sams, Lorisco Life CEO.

“We are proud to enable a more personalized approach to longevity and actuarial technology for our partners and clients. PREADISAN forecasts will further aid the focus of longevity and health in the future of financial planning and life settlements.” – Jay Jackson, Abacus Chairman and CEO.